This study is recruiting individuals who are currently on Wegovy (1.7 mg or 2.4 mg), or Zepbound (10 mg or 15 mg). Individuals must have been on a stable dose for the last 90 days, achieved approximately 8% weight loss, and have a stable weight. Individuals who are taking a compounded GLP-1 are not eligible. Individuals must actually be on Wegovy from Novo Nordisk or Zepbound from Eli Lilly. 

Eligible patients will be randomized to: 

1. remain on their weekly injectable, or 

2. A low dose daily, oral GLP-1, or 

3. A high dose daily, oral GLP-1

The study duration includes screening, a 4-week lead-in period, and 3 months on the trial.

Compensation is: ~$5K, up to $50 in monthly gym memberships, daily lunch and dinner catered by BistroMD, protein shakes, and reimbursement of copays for Zepbound or Wegovy for up to 12 months after completion of the study.

If you fit this criteria, please fill out your information below, including what dosage of Wegovy or Zepbound you are currently taking. We will get back to you within 24-48 hours and conduct a phone pre-screening if applicable. Thank you!